For the latest COVID-19 campus news and resources, visit umassmed.edu/coronavirus.

Search Close Search
Page Menu

Beth A. McCormick, PhD

Research Focus - Microbial-Based Cancer Therapy

  • Advancing preclinical development of novel microbial-based anticancer therapeutic agents
  • Investigating the interplay between microbes, tumors, and the immune system
  • Developing next-generation microbial therapeutics for multidrug resistance

Representative Publication

Mercado-Lubo R, Zhang Y, Zhao L, et al. A Salmonella nanoparticle mimic overcomes multidrug resistance in tumors. Nat Commun. 2016;7:12225

Read Publication

More Publications

In the News

Getting Results…
  • New study of oral therapy candidate indicates positive results for patients with mild-to-moderate COVID-19
    Research News

    New study of oral therapy candidate indicates positive results for patients with mild-to-moderate COVID-19

    New research by Kaleido Biosciences, Inc., and UMass Medical School’s John P. Haran, MD, PhD, and Beth McCormick, PhD, shows that the company’s microbiome metabolic therapy candidate produced positive results in patients with mild-to-moderate COVID-19.

    Read more
  • Novel therapeutic, based on UMMS microbiome discoveries and licensed by Bacainn Therapeutics, targets ulcerative colitis
    Research News

    Novel therapeutic, based on UMMS microbiome discoveries and licensed by Bacainn Therapeutics, targets ulcerative colitis

    Discoveries made by Beth McCormick, PhD, and licensed by Bacainn Therapeutics, Inc. are heading to Phase I clinical trials for ulcerative colitis and other diseases associated with uncontrolled inflammation in the gut.

    Read more